sponsored
PatientsVille.com Logo

PatientsVille

Elisor Medical Research Studies

Up-to-date List of Elisor Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Elisor Medical Research Studies

Rank Status Study
1 Recruiting Pravastatin for Prevention of Preeclampsia
Condition: Preeclampsia
Interventions: Drug: Pravastatin;   Drug: Placebo
Outcome Measures: Number and type of maternal adverse events;   Number and type of fetal/neonatal adverse events;   Pharmacokinetic parameters of pravastatin sodium during pregnancy
2 Unknown  Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
Conditions: Esophageal Cancer;   Stomach Cancer
Intervention: Drug: Pravastatin
Outcome Measures: all cause mortality;   free time of disease recurrence
3 Recruiting Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
Conditions: Hepatocellular Carcinoma;   CHILD B
Interventions: Drug: sorafenib;   Drug: Pravastatin;   Drug: Sorafenib + Pravastatin;   Other: patients receiving best supportive care
Outcome Measures: Time to radiologic progression;   Overall survival;   Survival without progression;   Time to treatment failure;   Objective response rate at four months;   Number and description of AE for toxicity and SAE;   Quality of life
4 Recruiting Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Refractory Anemia With Excess Blasts;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: pravastatin sodium;   Drug: idarubicin;   Drug: cytarabine;   Other: laboratory biomarker analysis
Outcome Measures: Number of participants with good CR;   Number of participants with TRM;   Relapse free survival;   Overall survival;   Biomarkers associated with clinical responses
5 Recruiting The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris
Conditions: Coronary Disease;   Hypercholesterolemia
Intervention: Drug: pravastatin, rosuvastatin
Outcome Measures: the percent change in fibrous cap thickness by optical coherence tomography;   the percent change and the absolute change from baseline in coronary plaque volume and IB signal obtained by IB-IVUS;   the absolute change from baseline in number of TCFA and plaque rupture, and in neointima thickness on stent struts by OCT;   the percent change and the absolute change from baseline in total cholesterol and LDL cholesterol
6 Recruiting A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT
Condition: Coronary Artery Occlusive Disease
Interventions: Drug: Pravastatin 40mg;   Drug: Rosuvastatin
Outcome Measure: Change of carotid intima media thickness 1 year after pravastatin or rosuvastatin treatment
7 Recruiting Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
Condition: Advanced Hepatocarcinoma
Intervention: Drug: Pravastatin
Outcome Measures: Overall survival;   Time to progression;   time to symptomatic progression (TTSP).
8 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
Outcome Measure: per cent changes of LDL cholesterol, comparison between the 2 treatment regimens
9 Recruiting S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: cytarabine;   Drug: idarubicin;   Drug: pravastatin sodium
Outcome Measures: Complete remission (CR) rate (including CR with incomplete recovery);   Relapse-free survival;   Overall survival;   Toxicity as assessed by NCI CTCAE version 4.0;   Correlation between pre-study cytogenetic features and response
10 Recruiting The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose
Condition: Diabetes
Interventions: Drug: Pravastatin;   Drug: Rosuvastatin;   Drug: Control
Outcome Measures: Glucose homeostasis;   Some biomarkers of diabetes;   Progression of glucose homeostasis;   Chronic complications of diabetes;   Incidence of diabetes
11 Unknown  Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study
Condition: Acute Myocardial Infarction
Intervention: Drug: Pravastatin
Outcome Measures: Combination of death, non-fatal myocardial infarction, unstable angina, coronary revascularization (except anticipated revascularization before randomization), non-fatal stroke and re-hospitalization due to heart failure or other cardiac causes.;   Each component of the primary outcome measures.
12 Unknown  Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study
Condition: Crohn's Disease
Intervention: Drug: Pravastatin
Outcome Measure: Primary outcome will be clinical benefit which will be defined as a decrease in HBI, fecal lactoferrin, CRP and/or ESR at 6 weeks compared with baseline values
13 Not yet recruiting Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis
Condition: Endometriosis
Intervention: Drug: Pravastatin
Outcome Measure: pain
14 Not yet recruiting Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis
Condition: Endometriosis
Intervention: Drug: Pravastatin
Outcome Measure: Linear Analogue Scale (LAS) for pain
15 Recruiting Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
Condition: Fibrosis
Intervention: Drug: Pravastatin
Outcome Measures: regression of radio-induced fibrosis (RIF) evaluated by high frequency ultrasound;   Fibrosis grade according to NCI-CTCAE v4 toxicities scale.;   Quality of life
16 Not yet recruiting COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial
Condition: Coronary Artery Disease
Interventions: Drug: Atorvastatin 40mg;   Drug: pravastatin 20 mg
Outcome Measures: Change of neointimal patterns assessed by 1-year followed OCT;   stent coverage and neointimal thickness;   Major adverse cardiac events
17 Recruiting Open Label Study for the Functional Characterization of Drug Metabolism and Transport
Condition: Drug Metabolism, Genotype-related
Interventions: Drug: Codeine;   Drug: Midazolam;   Drug: pravastatin;   Drug: Talinolol;   Drug: torsemide
Outcome Measures: Blood levels and clearance (dose/AUC) of midazolam;   Blood levels and clearance (dose/AUC) of torsemide;   Blood levels and clearance (dose/AUC) of codeine;   Blood levels and clearance (dose/AUC) of talinolol;   Blood levels and clearance (dose/AUC) of pravastatin;   determine metabolite profile
18 Recruiting Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
Condition: Drug-eluting Stent (DES)
Interventions: Drug: Atorvastatin (High dose statin treatment);   Drug: Pravastatin (High dose statin treatment)
Outcome Measures: the composite of death from any cause;   cardiac or non-cardiac death
19 Recruiting Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery
Condition: Coronary Artery
Interventions: Drug: Pravastatin 20mg/day for 12 months after randomization;   Drug: Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
Outcome Measure: Occurrence of the composite of death from any cause
20 Recruiting Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome
Conditions: Nephrotic Syndrome;   Hyperlipidemia
Intervention: Drug: Pravastatin
Outcome Measures: Changes in Microparticle tissue factor (MP-TF) activity;   Changes in plasma coagulation activation

These studies may lead to new treatments and are adding insight into Elisor etiology and treatment.

A major focus of Elisor research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Elisor